To the editor:
Several investigators have attempted to find the risk factors associated with persistent urgency and frequency after the relief of bladder outlet obstruction through transurethral prostate surgery (TPS), because persistent storage symptoms reduce the patients' satisfaction after surgery and additional treatment is necessary to control unresolved symptoms [1]. Most of the previous studies considered preoperative detrusor overactivity (DO) as one of the risk factors for persistent storage symptoms after surgery, and there have been various reports about the influence of preoperative DO on the surgical outcomes [2]. Some patients with persistent storage symptoms may benefit from medical therapy as antimuscarinic even after TPS. However, there has been little research as to whether antimuscarinics can alleviate voiding and storage symptoms and other symptoms in the patients during the early post-operative period after TPS. We have carefully read the article published in Investigative and Clinical Urology by Kim et al. [3], and his findings are indeed interesting. This article was a randomized, double-blinded, placebo-controlled study including 64 patients; they suggest that anticholinergics have a potential role in improving storage symptoms during the early post-operative period of TPS. Solifenacin reduced the storage symptoms of patients after PVP, although there were no significant differences compared with the storage symptoms of the placebo group [3]. However, in our opinion, storage symptom of early post-operative period of TPS may have been induced by inflammation of the prostatic urethra or edema that occurred during TPS, which could be one of the limitations of the study [4]. Authors have to give a clear explanation about this matter. Despite these limitations, the present study raises awareness to the readers about managing post-operative storage symptoms after TPS.
Footnotes
CONFLICTS OF INTEREST: The authors have nothing to disclose.
- Research conception and design: Yu Seob Shin and Sung Chul Kam.
- Drafting of the manuscript: Yu Seob Shin.
- Critical revision of the manuscript: Yu Seob Shin and Sung Chul Kam.
- Approval of final manuscript: Yu Seob Shin and Sung Chul Kam.
References
- 1.Antunes AA, Iscaife A, Reis ST, Albertini A, Nunes MA, Lucon AM, et al. Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? J Urol. 2015;193:2028–2032. doi: 10.1016/j.juro.2014.12.095. [DOI] [PubMed] [Google Scholar]
- 2.Kageyama S, Watanabe T, Kurita Y, Ushiyama T, Suzuki K, Fujita K. Can persisting detrusor hyperreflexia be predicted after transurethral prostatectomy for benign prostatic hypertrophy? Neurourol Urodyn. 2000;19:233–240. doi: 10.1002/(sici)1520-6777(2000)19:3<233::aid-nau4>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
- 3.Kim SJ, Bae WJ, Kim SW. Influence of solifenacin on the improvement of storage symptoms in the early period after photoselective vaporization of the prostate. Investig Clin Urol. 2019;60:480–487. doi: 10.4111/icu.2019.60.6.480. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Shin YS, Zhang LT, You JH, Choi IS, Zhao C, Park JK. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial. Clin Interv Aging. 2016;11:1301–1307. doi: 10.2147/CIA.S115042. [DOI] [PMC free article] [PubMed] [Google Scholar]
